Gateway Investment Advisers LLC Vertex Pharmaceuticals Inc Transaction History

Gateway Investment Advisers LLC

$8.79 Billion
Q2 2024

A detailed history of Gateway Investment Advisers LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gateway Investment Advisers LLC holds 67,959 shares of VRTX stock, worth $31.4 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares

67,959

Previous 69,502 2.22%

Holding current value

$31.4 Million

Previous $29.1 Million 9.64%

% of portfolio

0.36%

Previous 0.33%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 12, 2024	SELL	$392.81 - $485.53 $606,105 - $749,172	-1,543 Reduced 2.22%	67,959 $31.9 Million
Q1 2024 Apr 12, 2024	SELL	$407.69 - $446.08 $1.85 Million - $2.03 Million	-4,542 Reduced 6.13%	69,502 $29.1 Million
Q4 2023 Jan 09, 2024	BUY	$343.0 - $410.68 $746,368 - $893,639	2,176 Added 3.03%	74,044 $30.1 Million
Q3 2023 Oct 19, 2023	SELL	$338.18 - $362.46 $39,228 - $42,045	-116 Reduced 0.16%	71,868 $25 Million
Q2 2023 Jul 13, 2023	BUY	$314.42 - $351.91 $1,886 - $2,111	6 Added 0.01%	71,984 $25.3 Million
Q1 2023 Apr 11, 2023	SELL	$283.23 - $323.1 $67,691 - $77,220	-239 Reduced 0.33%	71,978 $22.7 Million
Q4 2022 Jan 13, 2023	SELL	$285.76 - $321.48 $1.2 Million - $1.35 Million	-4,207 Reduced 5.5%	72,217 $0
Q3 2022 Oct 07, 2022	BUY	$273.83 - $305.53 $1.44 Million - $1.6 Million	5,245 Added 7.37%	76,424 $22.1 Million
Q2 2022 Jul 13, 2022	SELL	$234.96 - $292.55 $3.78 Million - $4.7 Million	-16,074 Reduced 18.42%	71,179 $20.1 Million
Q1 2022 Apr 14, 2022	SELL	$221.42 - $260.97 $596,284 - $702,792	-2,693 Reduced 2.99%	87,253 $22.8 Million
Q4 2021 Jan 14, 2022	SELL	$177.01 - $223.45 $2.2 Million - $2.78 Million	-12,423 Reduced 12.14%	89,946 $19.8 Million
Q3 2021 Oct 22, 2021	SELL	$181.39 - $202.99 $160,348 - $179,443	-884 Reduced 0.86%	102,369 $18.6 Million
Q2 2021 Jul 13, 2021	SELL	$187.49 - $221.1 $2.41 Million - $2.85 Million	-12,869 Reduced 11.08%	103,253 $20.8 Million
Q1 2021 Apr 14, 2021	SELL	$207.02 - $241.31 $539,494 - $628,853	-2,606 Reduced 2.19%	116,122 $25 Million
Q4 2020 Jan 14, 2021	SELL	$207.01 - $276.09 $142,215 - $189,673	-687 Reduced 0.58%	118,728 $28.1 Million
Q3 2020 Oct 19, 2020	SELL	$255.65 - $303.1 $1.49 Million - $1.77 Million	-5,843 Reduced 4.66%	119,415 $32.5 Million
Q2 2020 Jul 15, 2020	SELL	$225.48 - $295.8 $3.37 Million - $4.42 Million	-14,930 Reduced 10.65%	125,258 $36.4 Million
Q1 2020 Apr 13, 2020	SELL	$199.77 - $247.81 $964,889 - $1.2 Million	-4,830 Reduced 3.33%	140,188 $33.4 Million
Q4 2019 Jan 09, 2020	BUY	$166.71 - $223.91 $546,642 - $734,200	3,279 Added 2.31%	145,018 $31.8 Million
Q3 2019 Oct 15, 2019	SELL	$166.23 - $187.09 $1.11 Million - $1.25 Million	-6,705 Reduced 4.52%	141,739 $24 Million
Q2 2019 Jul 17, 2019	SELL	$164.61 - $190.37 $40,494 - $46,831	-246 Reduced 0.17%	148,444 $27.2 Million
Q1 2019 Apr 10, 2019	BUY	$163.73 - $194.7 $127,709 - $151,866	780 Added 0.53%	148,690 $27.4 Million
Q4 2018 Jan 14, 2019	BUY	$151.91 - $192.21 $2.4 Million - $3.04 Million	15,796 Added 11.96%	147,910 $24.5 Million
Q3 2018 Oct 16, 2018	SELL	$167.73 - $192.74 $48,641 - $55,894	-290 Reduced 0.22%	132,114 $25.5 Million
Q2 2018 Jul 11, 2018	SELL	$145.72 - $169.96 $364,445 - $425,069	-2,501 Reduced 1.85%	132,404 $22.5 Million
Q1 2018 Apr 12, 2018	SELL	$151.6 - $177.13 $385,670 - $450,618	-2,544 Reduced 1.85%	134,905 $22 Million
Q4 2017 Jan 17, 2018	SELL	$137.28 - $155.55 $12,492 - $14,155	-91 Reduced 0.07%	137,449 $20.6 Million
Q3 2017 Oct 16, 2017	BUY	$148.13 - $162.24 $20.4 Million - $22.3 Million	137,540	137,540 $20.9 Million

Others Institutions Holding VRTX

# of Institutions

1,708

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gateway Investment Advisers LLC with notifications on news.

Account

Gateway Investment Advisers LLC Vertex Pharmaceuticals Inc Transaction History